A well-timed bridge investment can mean the difference between stalling and scaling. Dr. Asel Sartbaeva, CEO and co-founder of EnsiliTech, reflects on how family office support provided crucial bridge, enabled better deal terms, and positioned the company to close an oversubscribed £4.5 million round.

Bringing the world’s first insect vaccine from discovery to commercial reality marks a defining milestone for Dalan Animal Health. Annette Kleiser, CEO, shares how Dalan is now applying its innate immunity platform to aquaculture, advancing proof-of-concept in shrimp, and exploring broader species application.

Approval alone doesn’t guarantee commercial success. Robert Jordan shares how Vetirus Pharmaceuticals combines in-house regulatory expertise with early manufacturing planning, ensuring supply, shortening timelines to revenue, and enabling global expansion.

Scaling beyond limited early-stage momentum often calls for a disciplined corporate turnaround strategy. Jake Burlet outlines the practical steps CanBiocin took to shift from grant-to-grant R&D survival to a profitable growing enterprise through securing strategic investment.

Commercialising a new category of care requires more than product innovation. Rebecca Windsor, Director of Veterinary Affairs at Gallant, shares how education and developing trusted continuing education platforms have been central to preparing veterinarians for the clinical adoption of regenerative medicine.